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The link between changes in estimated glomerular ﬁltration rate (eGFR) and cigarette smoking was 
evaluated in Japanese male workers with a 5-year follow-up.  We examined the data of 456 Japanese 
male workers,  aged 22-70 years,  who were taking no medications,  and from this group,  286 men 
(43.5±8.2 years) were followed for 5-years.  Habits of cigarette smoking were obtained during inter-
views by well-trained staﬀ.  The inﬂuence of cigarette smoking on eGFR was evaluated.  In the ﬁrst 
analysis,  there was no signiﬁcant diﬀerence in eGFR between subjects with and without cigarette 
smoking.  In the second analysis,  eGFR was signiﬁcantly reduced after 5 years in all subjects.  Changes 
in eGFR in subjects with cigarette smoking (－1. 90±12. 31ml/min/1.73m2) were signiﬁcantly smaller 
than those in subjects without cigarette smoking (－4. 97±12. 05ml/min/1.73m2).  At follow-up,  we 
found that eGFR was weakly and negatively correlated with the number of cigarettes smoked (/day).  
The present study indicated that cigarette smoking may be an important modiﬁable factor for eGFR 
in Japanese male workers who are not taking any medications.
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igarette smoking has become an important pub-
lic health challenge,  and it has been reported 
that 39.4ｵ of men and 11.0ｵ of women are current 
smokers in Japan (http://www. mhlw. go. jp/hou-
dou/2008/12/dl/h1225-5j. pdf,  accessed on June 7,  
2010).  Cigarette smoking has been demonstrated to be 
a strong risk factor for atherosclerosis and cardiovas-
cular disease in a dose-dependent manner [1].
　 Chronic kidney disease (CKD) has also become an 
important public health challenge in Japan and it is a 
major risk factor for end-stage renal disease,  cardio-
vascular disease and premature death [2,  3].  
Identifying and treating risk factors for early CKD 
may be the best approach to prevent and/or delay 
adverse outcomes [2].  In Japan,  clinical practice 
guidelines established by the Japanese Society of 
Nephrology estimate that about 20ｵ of adults have 
CKD,  which is deﬁned as kidney damage or a glom-
erular ﬁltration rate (GFR)＜60ml/min/1.73m2 for at 
least 3 months regardless of cause [4],  and that 
about 4ｵ of adults have moderate or severe CKD 
(GFR＜50ml/min/1.73m2) [5].  
　 Revised equations for estimating GFR from serum 
creatinine were recently developed in Japan [6].  
Although previous studies showed that cigarette smok-
ing was closely linked to CKD and albuminuria 
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[7-10],  the link between eGFR using the new equa-
tions with Japanese subjects and cigarette smoking 
remains to be investigated.
　 Therefore,  in this study,  we investigated the link 
between eGFR and cigarette smoking in Japanese male 
workers who were not taking any medications with a 
5-year follow-up.  
Subjects and Methods
　 Subjects. Japanese male workers (n＝456),  
aged 22-70 years (46.4±9.2) were enrolled into this 
study (Table 1).  Subjects were not receiving any 
medications for diabetes,  hypertension and/or dys-
lipidemia at baseline.  
　 In a longitudinal analysis,  we used follow-up data 
of 286 subjects (43.5±8.2 years) selected from the 
456 subjects who met the following criteria: [1] 
received an annual health check-up at Kagawa Rosai 
Hospital in 2003 and 2008,  [2] received evaluation of 
cigarette smoking as part of the annual health check-
up.
　 Ethical approval for the study was obtained from 
the Ethical Committee of Kagawa Rosai Hospital,  
Japan.
　 Anthropometric measurements. Anthro-
pometric and body compositions were evaluated based 
on the subjectsｾ height and body weight.  Body mass 
index (BMI) was calculated by weight /[height]2 (kg/
m2) [11].
　 Cigarette smoking. The data on cigarette 
smoking was obtained at interviews by well-trained 
staﬀ in a structured way.  The subjects were asked if 
they currently smoked cigarettes.  When the answer 
was “yes”,  they were classiﬁed as current smokers,  
and at follow-up,  further questions were asked 
regarding the average number (pieces) of cigarettes 
smoked per day.  When the answer was “no”,  they 
were classiﬁed as non-smokers.  However,  we did not 
ask about the average number (pieces) of cigarettes 
smoked per day at baseline.
　 Blood pressure measurements. Blood pres-
sure of each participant was measured after the sub-
ject rested at least 15 min in the sitting position.
　 Blood sampling and assays. We measured 
overnight fasting serum levels of creatinine (enzy-
matic method),  high-density lipoprotein (HDL) choles-
terol,  triglycerides (L Type Wako Triglyceride･H,  
Wako Chemical,  Osaka) and blood sugar.  eGFR was 
calculated using the following equation: eGFR (ml/
min/1.73m2)＝194×Cr－1.094×Age－0.287[6].  Reduced 
eGFR was deﬁned as an eGFR＜60ml/min/1.73m2.
　 Statistical analysis. All data are expressed as 
mean ± standard deviation (SD) values.  Statistical 
analysis was performed using an unpaired t test and 
covariance analysis; p＜0.05 was considered to be 
statistically signiﬁcant.  Pearsonｾs correlation coeﬃ-
cients were calculated and used to test the signiﬁcance 
of the linear relationship among continuous variables.
Results
　 The measurements of age and eGFR in subjects 
with and without cigarette smoking recorded during 
the ﬁrst analysis are indicated in Table 2.  eGFR was 
signiﬁcantly correlated with age at baseline (r＝－0.329,  
p＜0.0001).  A total of 234 men (51.3ｵ) were current 
smokers and 10 of these men were diagnosed as having 
reduced eGFR.  There was a signiﬁcant diﬀerence of 
age between subjects with and without cigarette smok-
ing.  Therefore,  to avoid the inﬂuence of age on 
eGFR,  we used age as a covariate and compared 
eGFR using covariance analysis.  eGFR in subjects 
with cigarette smoking was similar to that in subjects 
without cigarette smoking after adjusting for age 
(Table 2).
　 The clinical parameters at the baseline and the 
5-year follow-up recorded during the second analysis 
are summarized in Table 3.  One hundred forty-ﬁve 
men were current smokers at baseline,  and 109 men 
were current smokers after 5 years.  eGFR was sig-
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Table 1　 Clinical proﬁles of 456 men
Number of subjects 456
Age 46.4±  9.2
Height (cm) 168.7±  6.1
Body weight (kg) 67.0±10.5
Body mass index (kg/m2) 23.5±  3.3
Systolic blood pressure (mmHg) 125.9±17.4
Diastolic blood pressure (mmHg) 77.9±17.4
Triglyceride (mg/dl) 120.8±91.7
HDLcholesterol (mg/dl) 59.7±17.2
Blood sugar (mg/dl) 95.3±23.2
Creatinine (mg/dl) 0.79±0.11
eGFR (ml/min/1.73m2) 86.3±15.1
Mean±SD
niﬁcantly decreased after 5 years and correlated with 
age at follow-up (r＝－0.264,  p＜0.0001).  The 
decline rate of eGFR was －0.68ml/min/1.73m2 per 
year.  One man at baseline and 12 men at follow-up 
were diagnosed as having reduced eGFR.  Triglyceride 
and blood glucose levels were also signiﬁcantly 
increased,  and HDL cholesterol was signiﬁcantly 
decreased after 5 years.  In addition,  eGFR was 
weakly correlated with the number of cigarettes 
smoked (/day) at follow-up (r＝－0.208,  p＝0.0310) 
(Fig.  1).  No signiﬁcant correlation was noted between 
number of cigarettes smoked per day and age (r＝
0.182,  p＝0.0503) at follow-up.
　 To evaluate the eﬀect of cigarette smoking on 
changes in eGFR,  we compared changes in eGFR 
between subjects with (n＝145) and without (n＝141) 
cigarette smoking at baseline and 5 years later.  There 
were no diﬀerences of age or eGFR at baseline.  
However,  changes in eGFR in subjects with cigarette 
smoking (－1.90±12.31ml/min/1.73m2) were signiﬁ-
cantly smaller than those in subjects without cigarette 
smoking (－4.97±12.05ml/min/1.73m2) after 5 years.  
There were no signiﬁcant diﬀerences in the changes in 
other clinical parameters between men with and with-
out cigarette smoking at the 5-year follow-up (Table 
4).
　 Finally,  in the current smokers at baseline (n＝
145),  we further investigated the changes in eGFR 
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Table 2　 Comprison of eGFR between men with and without cigarette smoking
Cigarette somoking (＋) Cigarette smoking (－) p p (After adjusting for age)
Number of subjects 234 222
Age 45.6±  9.4 47.3±  8.9 0.0390
eGFR (ml/min/1.73m2) 87.7±14.5 84.9±15.6 0.0503 0.1952
Mean±SD
Table 3　 Changes in clinical prameters in 286 men with a 5 year follow-up
Baseline Follow up p
Number of subjects 286
Age  43.5±  8.2
Height (cm) 169.4±  6.1
Body weight (kg)  67.8±11.0  68.0±11.1 0.3711
Body mass index (kg/m2)  23.6±  3.5  23.7±  3.5 0.1935
Systolic blood pressure (mmHg) 124.0±16.4 124.4±16.9 0.6616
Diastolic blood pressure (mmHg)  76.6±11.5  77.8±11.5 0.0625
Triglyceride (mg/dl) 112.0±74.5 126.1±113 0.0093
HDLcholesterol (mg/dl)  61.3±18.3  59.5±16.3 0.0087
Blood sugar (mg/dl)  92.0±14.9  95.8±22.9 0.0010
Creatinine (mg/dl)  0.79±0.11  0.80±0.12 0.1322
eGFR (ml/min/1.73m2)  87.9±14.5  84.5±14.5 ＜0.0001
Mean±SD
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Fig. 1　 Simple correlation analysis between eGFR and number of 
cigarettes smoked (/day) in Japanese male workers who were tak-
ing no medications.
between subjects with (n＝109) and without (n＝39) 
cigarette smoking at follow-up.  There was no signiﬁ-
cant diﬀerence of eGFR between subjects with (89.6
±13.2ml/min/1.73m2) and without (86.1±12.9ml/
min/1.73m2) cigarette smoking after adjusting for age 
at baseline,  and there was no signiﬁcant diﬀerence in 
the changes in eGFR between subjects with (－1.92±
13.39ml/min/1.73m2) and without (－1.81±8.40ml/
min/1.73m2) cigarette smoking after adjusting at the 
5-year follow-up.
Discussion
　 The main goal of this study was to explore the link 
between eGFR and cigarette smoking in Japanese male 
workers who were taking no medications,  with a 5 
year follow-up.  eGFR was weakly and negatively cor-
related with the number of cigarettes smoked per day 
by cross-sectional analysis.  However,  longitudinal 
analysis showed that changes in eGFR in subjects with 
cigarette smoking were signiﬁcantly smaller than those 
in subjects without cigarette smoking.
　 Previous studies showed that cigarette smoking 
was associated with CKD.  Sawicki et al.  reported 
that cigarette smoking increased proteinuria in 
patients with CKD [12].  Orth et al.  [13] and 
Ejerblad et al.  [14] also reported that cigarette 
smoking promoted renal dysfunction.  In this study,  by 
cross-sectional analysis,  eGFR was weakly and nega-
tively correlated with the number of cigarettes smoked 
per day in Japanese male workers who were taking no 
medications.  In agreement with this result,  Ritz et al.  
reported that GFR decreased during smoking,  and this 
was accompanied by a signiﬁcant decrease of ﬁltration 
fraction and an increase in renovascular resistance.  In 
addition,  these ﬁndings were reproduced with nico-
tine-containing chewing gum [15].  
　 On the other hand,  we showed that cigarette smok-
ing was associated with preventing a decline of eGFR 
in Japanese male workers who were taking no medica-
tions,  with a 5 year follow-up.  There were no signiﬁ-
cant diﬀerences in changes in other clinical parame-
ters between subjects with and without cigarette 
smoking in the second analysis.  Some studies have 
shown that current smoking is associated with higher 
creatinine clearance or GFR in the general population 
[16] and in patients with type 2 diabetes mellitus 
[17].  Pinto-Sietsma et al.  also reported that current 
smoking showed a dose-dependent association with 
elevated eGFR in nondiabetic subjects,  which disap-
peared after smoking ceased [18].  Although the 
mechanism of this higher renal function in current 
smokers is unknown,  it is possible that vasodilatory 
compounds such as nitric oxide and atrial natriuretic 
peptide repeatedly released after each cigarette 
smoked eventually cause chronic glomerular hyperﬁl-
tration [19,  20].  Hormones such as vasopression or 
adrenocorticoid hormone may also play a role [21].  
　 Does this prevention of low eGFR in current smok-
ers mean a better renal function? It should be noted 
that glomerular hyperﬁltration represents a new 
marker of clustering of metabolic risk factors even 
before overt features of cardiovascular disease are 
manifest [22].  It was also demonstrated in animal 
models that hyperﬁltration is associated with 
increased intraglomerular capillary pressure,  which 
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Table 4　 Comparison of eGFR and changes in parameters between men with and without cigarette smoking at baseline
Cigarette smoking (＋) Cigarette smoking (－) p
Number of subjects 145 141
Age 42.5±  8.3 44.4±  8.1 0.0526
eGFR (ml/min/1.73m2) 88.7±13.2 87.0±15.7 0.3917
Changes in eGFR (ml/min/1.73m2) －1.9±12.3 －5.0±12.1 0.0336
Changes in body weight (kg)  0.4±  4.5  0.8±  3.5 0.5714
Changes in BMI (kg/m2)  0.1±  1.5  0.1±  1.3 0.8970
Changes in systolic blood pressure (mmHg)  1.0±15.8 －0.3±15.0 0.4699
Changes in diastolic blood pressure (mmHg)  2.3±10.9  0.0±  9.5 0.0586
Changes in triglyceride (mg/dl) 18.5±110.5  9.6±65.4 0.4069
Changes in HDL cholesterol (mg/dl) －1.0±10.4 －2.5±11.7 0.2323
Changes in blood sugar (mg/dl)  4.9±18.8  2.7±19.9 0.3542
Mean±SD
results in proteinuria reﬂecting glomerulosclerosis 
lesions [23].  Therefore,  an increase in eGFR caused 
by cigarette smoking may not simply be a preferable 
outcome or an innocuous observation.  In fact,  our 
study showed,  in a cross-sectional analysis,  that 
eGFR was weakly and negatively correlated with the 
number of cigarettes smoked (/day),  and some reports 
show that cigarette smoking was critically involved in 
CKD [7-10].  
　 This study had a number of potential limitations.  
First,  the 456 male workers who were taking no 
medications in our study underwent annual health 
check-ups,  indicating that they were probably more 
health-conscious than the average person.  Second,  we 
could not prove the mechanism of the link between 
eGFR and cigarette smoking.  Third,  at follow-up we 
could not obtain the data of the average number of 
cigarettes smoked per day at baseline or subjectｾ age 
when they started smoking.  Subjects who smoked 
before the date of the ﬁrst analysis but who had 
stopped by then would have therefore been catego-
rized as non-smokers.  
　 In conclusion,  cigarette smoking is a modiﬁable 
factor for eGFR in Japanese male workers who are 
taking no medications.  We may need to take into 
account an individualｾs smoking status when assessing 
eGFR and the prevalence of CKD.  Further long-term 
analysis by using this cohort is required,  and microal-
buminuria should be measured to address these issues.
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